Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma

References

• To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. doi:10.1186/1471-2458-12-204.
   PubMed Web of Science ®Google Scholar
• Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2021. Available from: https://ginasthma.org/ [last accessed 6 May 2021].
   Google Scholar
• Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R, Castro M, Curran-Everett D, Fitzpatrick AM, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi:10.1164/rccm.200906-0896OC.
   PubMed Web of Science ®Google Scholar
• Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020;125(2):171–176. doi:10.1016/j.anai.2020.04.011.
   PubMed Web of Science ®Google Scholar
• McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013;73(11):1197–1212. doi:10.1007/s40265-013-0085-4.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221.
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.12815.
   PubMed Web of Science ®Google Scholar
• Novartis. Product Sales. 2020. Available from: https://www.novartis.com/investors/financial-data/product-sales [last accessed 26 April 2021].
   Google Scholar
• Sánchez J, Morales E, Santamaria L-C, Acevedo A-M, Calle A, Olivares M, Gomez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021;14(3):100520. doi:10.1016/j.waojou.2021.100520.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Mark FitzGerald J, Canadian Respiratory Research Network. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;16:3. doi:10.1186/s12962-018-0089-8.
   PubMed Web of Science ®Google Scholar
• Hong SH, Cho JY, Kim TB, Lee EK, Kwon SH, Shin JY. Cost-effectiveness of tiotropium in elderly patients with severe asthma using real-world data. J Allergy Clin Immunol Pract. 2021;9(5):1939–1947.e7.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302–308. doi:10.1111/j.1398-9995.2004.00770.x.
   PubMed Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy. 2014;12(4):447–459. doi:10.1007/s40258-014-0107-8.
   PubMedGoogle Scholar
• NICE. Glossary. 2021. Available from: https://www.nice.org.uk/glossary?letter=u [last accessed 3 October 2021].
   Google Scholar
• Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563. doi:10.3111/13696998.2015.1025793.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27. doi:10.3132/pcrj.2007.00002.
   PubMedGoogle Scholar
• (DANE) DNdE. Archivo nacional de datos. 2019. Available from: https://sitios.dane.gov.co/anda-index/ [last accessed 3 October 2021].
   Google Scholar
• Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836–844. doi:10.1164/rccm.200401-033OC.
   PubMed Web of Science ®Google Scholar
• Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin. 2014;30(7):1427–1436. doi:10.1185/03007995.2014.908828.
   PubMed Web of Science ®Google Scholar
• Florez-Tanus A, Parra D, Zakzuk J, Caraballo L, Alvis-Guzman N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26. doi:10.1186/s40413-018-0205-4.
   PubMed Web of Science ®Google Scholar
• Miranda P. [The effectiveness of omalizumab in the control of severe uncontrolled asthma in Latin America. An exploratory systematic review and meta-analysis]. Rev Alerg Mex. 2020;67(1):19–24.
   PubMedGoogle Scholar
• Instituto de Evaluación Tecnológica en Salud. Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogota DC. 2014. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf [last accessed 3 October 2021].
   Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, CHEERS Task Force, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1–e5. doi:10.1016/j.jval.2013.02.010.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206. doi:10.1016/j.rmed.2016.06.013.
   PubMed Web of Science ®Google Scholar